GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Hepion Pharmaceuticals
Hess is a major independent oil and gas company. Its share price reflects not only oil prices but also the enormous success of its partnership with Exxon in discovering giant fields in Guyana, which has been the main driver of its value. The expected acquisition by Chevron will change its history.
Share prices of companies in the market segment - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for liver diseases such as non-alcoholic steatohepatitis (NASH). We have classified the company in the Pharma: Liver category. The chart below shows investor sentiment in this promising segment.
Broad Market Index - GURU.Markets
Hepion Pharmaceuticals is a biotech company developing drugs to treat nonalcoholic steatohepatitis (NASH) and other liver diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Hepion shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
HEPA - Daily change in the company's share price Hepion Pharmaceuticals
Hepion Pharmaceuticals' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its liver disease drugs.
Daily change in the price of a set of shares in a market segment - Pharma liver
Hepion Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as nonalcoholic steatohepatitis. This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical HEPA dynamics are for this niche.
Daily change in the price of a broad market stock, index - GURU.Markets
Hepion Pharmaceuticals is a biotech company specializing in the treatment of liver diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Hepion Pharmaceuticals
For Hepion Pharmaceuticals, the year-end trend is a story about the development of its drug for the treatment of non-alcoholic steatohepatitis (NASH). Its 12-month market capitalization is entirely dependent on clinical trial data. The success of its lead candidate could offer a new approach to treating this common liver disease.
Annual dynamics of market capitalization of the market segment - Pharma liver
Hepion, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its liver disease drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Hepion Pharmaceuticals is a classic biotech company whose fate is decided in the lab. Its year-over-year performance compared to the S&P 500 tells a story not about economics, but about investors' faith in the success of its liver disease treatments. Any news of progress or setback could change everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Hepion Pharmaceuticals
Hepion is a clinical-stage biopharmaceutical company focused on liver diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its lead drug is a binary outcome event for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases, particularly nonalcoholic steatohepatitis (NASH). This represents a huge potential market. The dynamics of the biotech sector reflect the hopes of developing the first effective treatment. Hepion's story is one of a risky race, in which it is just one of many participants.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases, particularly nonalcoholic steatohepatitis (NASH). The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how scientific data has impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases such as NASH. Its weekly stock price is highly volatile and depends on news of clinical trial results.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Hepion Pharmaceuticals develops drugs to treat liver diseases such as nonalcoholic steatohepatitis (NASH). This is a huge market, but also a very challenging target. The chart will show whether Hepion's share price movements are a reaction to news about its research or reflect the general hopes and disappointments in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Hepion is a clinical-stage biotech. Its shares rely on trial news, not macroeconomics. The chart clearly demonstrates how disconnected the company's performance is from the stock market and follows its own scientific calendar.
Market capitalization of the company, segment and market as a whole
HEPA - Market capitalization of the company Hepion Pharmaceuticals
Hepion Pharmaceuticals' market capitalization is the chart of a clinical-stage biotech company focused on liver disease (MASH). Its volatile chart is driven by news about the progress of its clinical trials. This is a high-risk bet that its drug will be successful in this vast and competitive market.
HEPA - Share of the company's market capitalization Hepion Pharmaceuticals within the market segment - Pharma liver
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as NAFLD. Its market share in the pharmaceutical sector is minimal. Its market capitalization reflects investor expectations for the success of its clinical trials in one of the most in-demand areas of medicine.
Market capitalization of the market segment - Pharma liver
Here's a chart showing the biotech sector's market capitalization. Hepion Pharmaceuticals is a company focused on treating NASH (non-alcoholic steatohepatitis), the "silent epidemic" of our time. The potential of this market is enormous. Hepion's performance against this backdrop is a risky bet that its drug could become the first effective treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
Hepion is a biopharmaceutical company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). Its market capitalization reflects its bet on developing a therapy for this common condition. The chart below shows the weighting of biotech companies in this field.
Book value capitalization of the company, segment and market as a whole
HEPA - Book value capitalization of the company Hepion Pharmaceuticals
Hepion Pharma's book value is derived from its intellectual property rights to the drug renkofigstat, which is used to treat metabolic liver diseases (NASH). The chart tells the story of a biotech company investing its capital in clinical trials, building an intangible foundation in one of the largest and most complex areas of medicine.
HEPA - Share of the company's book capitalization Hepion Pharmaceuticals within the market segment - Pharma liver
Hepion Pharmaceuticals develops drugs to treat liver diseases. The chart shows its share of actual R&D assets. These are its laboratories where drugs are being developed to combat liver fibrosis and cancer.
Market segment balance sheet capitalization - Pharma liver
Hepion Pharmaceuticals is a biopharmaceutical company working on treatments for liver diseases such as NASH. Their value is created in the lab. A book value chart will show their R&D base, but it won't reflect the potential value of their scientific developments.
Book value of all companies included in the broad market index - GURU.Markets
Hepion Pharmaceuticals' balance sheet includes laboratories and R&D centers developing drugs for liver diseases such as non-alcoholic steatohepatitis (NASH). The chart shows how the company built its scientific and material capital.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Hepion Pharmaceuticals
Hepion Pharmaceuticals develops drugs to treat liver diseases such as NASH. Its assets are patents. The chart below visualizes its hopes for solving a major medical problem. Market capitalization represents investors' bet that the company's drug will be successful and in demand.
Market to book capitalization ratio in a market segment - Pharma liver
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Its valuation is based on the potential of its developments in this vast but complex area. The chart reflects the high risk and high investor expectations.
Market to book capitalization ratio for the market as a whole
Hepion Pharmaceuticals develops drugs for the treatment of liver diseases. Like most biotech companies in the development stage, its market value is not tied to tangible assets. This metric demonstrates that the company's valuation is a bet by investors on the successful completion of clinical trials and future sales of the drug.
Debts of the company, segment and market as a whole
HEPA - Company debts Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biotechnology company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). This chart reflects its financial position. The company has no revenue and funds its lengthy and expensive clinical trials through equity issuance.
Market segment debts - Pharma liver
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as nonalcoholic steatohepatitis (NASH). This market has enormous potential, but is highly competitive. This chart illustrates the company's financial risk in its race to develop an effective treatment.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Hepion Pharmaceuticals
Hepion Pharmaceuticals is a biopharmaceutical company developing treatments for liver diseases. This chart shows its financial structure. For a company in the clinical trials stage, without stable revenue, debt is a significant risk.
Market segment debt to market segment book capitalization - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases. This chart shows the debt burden in the biotech sector, a key indicator of a company's ability to fund its expensive research and development.
Debt to book value of all companies in the market
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as NASH. This is a vast but complex field of research. This chart of total market debt demonstrates how favorable the investment climate is overall for funding companies working on such common but difficult-to-treat diseases.
P/E of the company, segment and market as a whole
P/E - Hepion Pharmaceuticals
Hepion Pharmaceuticals is a biotech company developing drugs to treat nonalcoholic steatohepatitis (NASH) and other liver diseases. This chart reflects the high risks in this complex field, where many companies have failed. The company's performance depends entirely on clinical trial results.
P/E of the market segment - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biotech focused on developing drugs to treat nonalcoholic steatohepatitis (NASH), a serious liver disease associated with obesity. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value companies working to address this growing healthcare problem.
P/E of the market as a whole
Hepion Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). Its valuation is entirely dependent on the success of its drugs in clinical trials. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Hepion Pharmaceuticals
Hepion Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart reflects market expectations for the success of its clinical programs. Future revenue depends on a breakthrough in the treatment of this common disease.
%20P%2FE%20Hepion%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Hepion-Pharmaceuticals&v=1772656083419 "Chart of the company's future (projected) P/E Hepion Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The chart reflects average profitability expectations for the biotech sector. HEPA's position relative to this benchmark reflects investors' bet on their ability to solve this complex and widespread problem.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772656083455 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart of overall market expectations shows how willing investors are to invest in companies operating in complex therapeutic areas with huge potential markets.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772656083579 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. Its financial schedule is driven by research expenses. Potential profitability depends on successful treatment of this widespread disease.
Profit of companies in the market segment - Pharma liver
Hepion Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This is a huge but challenging market to develop. This chart shows the overall profitability of this segment. It reflects the overall progress of the industry in treating liver diseases and the investment attractiveness of this area.
Overall market profit
Hepion Pharmaceuticals is developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This represents a huge potential market. The company's success depends on the results of clinical trials. The positive economic environment, as shown in this chart, is important for raising the capital needed to conduct large-scale research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart reflects analysts' speculative expectations regarding the potential of its candidates in this large but complex therapeutic area.
%20profit%20of%20the%20company%20Hepion%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Hepion-Pharmaceuticals&v=1772656083825 "Graph of future (projected) profit of the company Hepion Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma liver
Hepion Pharmaceuticals is a biotechnology company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's future depends on the success of its clinical programs. This chart reflects forecasts for the entire pharmaceutical sector, providing context for assessing Hepion's potential to treat one of the most common liver diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772656083845 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Hepion Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of liver diseases. Its success depends on the results of clinical trials and regulatory approval. The overall economic forecasts shown in this chart are of minimal importance to the company at this stage.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772656083894 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Hepion Pharmaceuticals
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). This chart shows the market valuation of its developments in one of the most complex and competitive areas of medicine. The dynamics depend entirely on the results of clinical trials.
P/S market segment - Pharma liver
Hepion Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. Future revenue depends on the success of its clinical programs. This pharma chart reflects investor expectations for Hepion's potential to address one of the most common problems in hepatology.
P/S of the market as a whole
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat nonalcoholic steatohepatitis (NASH), a serious liver disease. This market revenue valuation chart helps understand how investors view the company's potential to treat a disease that affects millions of people but currently has no approved treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart shows how the market perceives the future commercial potential of its lead candidate in the vast but competitive liver disease market.
%20P%2FS%20Hepion%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Hepion-Pharmaceuticals&v=1772656084025 "The graph of the company's future (projected) P/S Hepion Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biotech company developing a drug for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease. The company's valuation reflects the huge potential market for this disease, but also the very high risks, as many companies have failed in this area.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772656084069 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). This represents a huge potential market. In the context of the overall revenue projections shown in the chart, Hepion represents a venture investment in the future of hepatology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772656084106 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biotechnology company developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company currently has no commercial products and, consequently, no sales revenue.
Sales of companies in the market segment - Pharma liver
Hepion Pharmaceuticals (HEPA) is a biopharmaceutical company developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. This metric reflects revenue in the pharmaceutical sector. Hepion is targeting the vast and growing market for liver diseases for which there are currently no approved treatments.
Overall market sales
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). Its success depends on the results of clinical trials. This pattern of overall economic activity affects the investment climate. During favorable periods, biotech companies find it easier to attract capital for lengthy and expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Hepion Pharmaceuticals
Hepion Pharmaceuticals is a biotechnology company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. Future revenue depends on the success of its lead candidate in clinical trials. This chart reflects analyst forecasts, which assess the likelihood of commercialization of its therapy in the vast liver disease market.
%20sales%20of%20the%20company%20Hepion%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Hepion-Pharmaceuticals&v=1772656084240 "Schedule of future (projected) sales of the company Hepion Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment of liver diseases such as non-alcoholic steatohepatitis (NASH). This graph shows the potential future revenue of their lead candidate. This is an analyst's view of the commercial prospects of their drug.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772656084246 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Hepion Pharmaceuticals develops drugs to treat nonalcoholic steatohepatitis (NASH) and other liver diseases. This is a huge market with no approved drugs. This chart illustrates the overall investment climate, but for Hepion, progress in clinical trials is key, potentially leading to the first effective treatment for NASH.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772656084273 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biotechnology company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease. Its financial performance reflects significant investments in R&D. The chart shows the company's current profitability as an investment in solving one of the most widespread and complex diseases of our time.
Market segment marginality - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart reflects its operating expenses. Future profitability is entirely dependent on the success of its clinical programs.
Market marginality as a whole
Hepion Pharmaceuticals is a clinical-stage biotech developing drugs for the treatment of liver diseases such as NAFLD. This total return chart reflects the investment climate. In a favorable economic environment, when investors are confident about the future, companies like Hepion find it easier to raise capital for lengthy and expensive research.
Employees in the company, segment and market as a whole
Number of employees in the company Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. This chart shows the size of the clinical team advancing the company's lead candidate through key phases of testing.
Share of the company's employees Hepion Pharmaceuticals within the market segment - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biotechnology company focused on treating liver diseases such as non-alcoholic steatohepatitis (NASH). Its staff consists of a team of scientists and clinicians. This chart shows the company's human resources dedicated to combating one of the most common chronic diseases of our time.
Number of employees in the market segment - Pharma liver
Hepion Pharmaceuticals develops drugs to treat liver diseases, particularly non-alcoholic steatohepatitis (NASH). This chart, which shows employment in hepatology, highlights the growing concern about this "silent epidemic." For Hepion, the growing number of specialists in this field indicates increased awareness and an expanding market for their therapeutic candidates.
Number of employees in the market as a whole
Hepion Pharmaceuticals is a biotech company specializing in the treatment of liver diseases such as nonalcoholic steatohepatitis (NASH). This represents a huge potential market. The growth in overall employment, reflected in this chart, indicates a healthy economy capable of funding the long-term clinical trials necessary to bring drugs to market for such common conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Hepion Pharmaceuticals (HEPA)
Hepion Pharmaceuticals (HEPA) is a biotech company focused on treating liver diseases (such as NAFLD). This biotech chart is an indicator of concentrated value. Market capitalization is based on expectations for clinical trials and patent value. A small team of scientists can create an asset worth billions.
%20of%20the%20company%20Hepion%20Pharmaceuticals%20(HEPA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Hepion-Pharmaceuticals-HEPA&v=1772656084710 "Chart of market capitalization per employee (in thousands of dollars) of the company Hepion Pharmaceuticals (HEPA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Hepion Pharmaceuticals develops drugs to treat liver diseases such as NAFLD. In biotech, market capitalization reflects clinical trial potential. This chart shows the enormous future value the market is placing on the work of a scientific team that can address this growing healthcare problem.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772656084720 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases, particularly non-alcoholic steatohepatitis (NASH). This chart for Hepion illustrates how, in biotech, market capitalization per employee can be very high, as the company is targeting a huge and unserved market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772656084776 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Hepion Pharmaceuticals (HEPA)
Hepion Pharmaceuticals is a biotech R&D company focused on treating liver diseases. The company is unprofitable. This graph will show a negative value—the loss per employee. This reflects the amount of capital the company burns through clinical research.
%20Chart%20Hepion%20Pharmaceuticals%20(HEPA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Hepion-Pharmaceuticals-HEPA&v=1772656084782 "Company Profit Per Employee (in thousands of dollars) Chart Hepion Pharmaceuticals (HEPA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Hepion Pharmaceuticals develops drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). In the highly competitive hepatology field, the productivity of the research team is crucial. This metric demonstrates the value each employee creates, which is an indicator of the effectiveness of the company's R&D platform.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772656084835 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Hepion Pharmaceuticals is a biotech company developing drugs to treat liver diseases, specifically NASH (non-alcoholic steatohepatitis). This chart shows the average profitability of one employee in the economy. It provides investors with context: the biotech sector operates in an all-or-nothing paradigm, where the return on personnel (scientists) can be enormous if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772656085005 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Hepion Pharmaceuticals (HEPA)
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. Because it has no commercial products yet, it has no revenue per employee. This chart clearly demonstrates the R&D phase, where all value is generated through scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Hepion-Pharmaceuticals-HEPA&v=1772656085039 "Sales chart per company employee Hepion Pharmaceuticals (HEPA)")
Sales per employee in the market segment - Pharma liver
Hepion Pharmaceuticals (HEPA) is a biotech company developing drugs to treat liver diseases, specifically nonalcoholic steatohepatitis (NASH). This chart shows the average income per employee in the sector. It is important for assessing the effectiveness of R&D and personnel structure compared to other biotechs in this niche.
Sales per employee for the market as a whole
Hepion Pharmaceuticals (HEPA) is a clinical-stage biopharmaceutical company focused on developing therapies for liver diseases, specifically non-alcoholic steatohepatitis (NASH). The company has no commercial revenue. This near-zero figure reflects ongoing investment in the team of scientists working on a treatment for this very common disease.
Short shares by company, segment and market as a whole
Shares shorted by company Hepion Pharmaceuticals (HEPA)
Hepion Pharmaceuticals (HEPA) is a biotech company trying to develop a treatment for NAFLD (NASH), or non-alcoholic steatohepatitis. This chart shows short interest. The high bearish bets reflect the fact that NASH is a drug company "graveyard," where dozens of drugs have failed, and investors are skeptical of HEPA's success. (346)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Hepion-Pharmaceuticals-HEPA&v=1772656085120 "Short Shares Chart for the Company Hepion Pharmaceuticals (HEPA)")
Shares shorted by market segment - Pharma liver
Hepion Pharmaceuticals (HEPA) is a biopharmaceutical company developing treatments for liver diseases such as NASH (non-alcoholic steatohepatitis). The chart below shows the overall short position in the biotech sector, demonstrating how skeptical investors are of success in this complex field.
Shares shorted by the overall market
Hepion Pharmaceuticals is a clinical-stage biotech developing a drug for NASH (liver disease). This is a highly competitive field of R&D. This chart measures general fear. When investors are afraid, they are reluctant to bet on "lottery tickets." They see HEPA as a money-burner in a race with giants and sell off shares, unwilling to take scientific risks.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Hepion Pharmaceuticals (HEPA)
Hepion Pharmaceuticals is a biotech company targeting the "holy grail" of hepatology—the treatment of nonalcoholic steatohepatitis (NASH). It's a huge but complex market. This graph is a "cardiogram" of hope. It overheats on any positive R&D data and cools off on news of failure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Hepion-Pharmaceuticals-HEPA&v=1772656085143 "RSI 14 indicator chart for the company's stock Hepion Pharmaceuticals (HEPA)")
RSI 14 Market Segment - Pharma liver
Hepion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment of liver diseases, specifically nonalcoholic steatohepatitis (MASH). This chart measures the overall momentum in the liver biotech sector. It helps us understand whether the HEPA trend is a response to its data or general hype.
RSI 14 for the overall market
Hepion Pharmaceuticals (HEPA) is a biotech company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HEPA (Hepion Pharmaceuticals)
Hepion Pharmaceuticals is a biopharmaceutical company focused on developing a therapy (Rencofilstat) for the treatment of NASH (MASH) – non-alcoholic steatohepatitis, or "fatty liver disease." This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HEPA-Hepion-Pharmaceuticals&v=1772656085178 "A chart showing analyst consensus forecasts for the expected stock price. HEPA (Hepion Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price HEPA (Hepion Pharmaceuticals)
Hepion is a biotech company that, like many others, is trying to "conquer" MASH (NASH), a disease known as fatty liver disease. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of its chances in this pharma "graveyard."
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HEPA-Hepion-Pharmaceuticals&v=1772656085180 "A chart showing the difference between the consensus forecast and the actual stock price. HEPA (Hepion Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Hepion Pharmaceuticals is a biotech company focused on treating fatty liver disease (NASH) and other liver diseases. This is risky R&D. This chart shows analysts' overall expectations for the liver pharmaceutical sector. It reflects whether experts believe a breakthrough can be achieved in this "graveyard" of R&D projects.
Analysts' consensus forecast for the overall market share price
Hepion Pharmaceuticals is a biotech company focused on treating fatty liver disease (NASH), one of the most complex and widespread diseases. This chart reflects the overall market "risk appetite." For Hepion, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Hepion Pharmaceuticals
Hepion Pharma is a biotech R&D company with an all-in-one bet on one of the most challenging targets in medicine: NASH (non-alcoholic steatohepatitis, fatty liver disease). This chart is a pure binary risk indicator. It doesn't reflect profit, but rather the market's speculative valuation of their (very risky) clinical data and their chances of success in this gold rush.
AKIMA Market Segment Index - Pharma liver
Hepion Pharmaceuticals is a biopharmaceutical company targeting the silent epidemic of non-alcoholic fatty liver disease (NASH). They are developing drugs to treat this complex condition. This chart compares their composite index to the sector, showing how their liver strategy compares to others.
The AKIM Index for the overall market
Hepion Pharmaceuticals, a biopharmaceutical company developing rencofilstat for the treatment of liver disease (NASH), announced it was shutting down operations. This chart, which reflects the market average, provides a macro backdrop. It helps assess how the drug development failure compares to overall economic trends.
